Shopping Cart

Your shopping cart is currently empty

Blonanserin (Alias: AD-5423)

Name: Blonanserin
Brand: TargetMol
SKU: T1180
Price: 29 USD
Availability: InStock
Rating: 5 (10 reviews)

Catalog No. T1180 Copy Product Info

Purity: 99.99%

😃Good

Blonanserin (AD-5423) is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.

Blonanserin

Copy Product Info

😃Good

Catalog No. T1180

Alias AD-5423

Cas No. 132810-10-7

Pack Size	Price	USA Stock	Global Stock
25 mg	$44	In Stock	In Stock
50 mg	$64	In Stock	In Stock
100 mg	$89	In Stock	In Stock
1 mL x 10 mM (in DMSO)	$29	In Stock	In Stock

In stock · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Cart

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Batch Information

Select Batch

Purity:99.99%

Appearance:Solid

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Blonanserin AI Summary

Blonanserin exhibits high binding affinity in in vitro assays against human dopamine receptor D2L (Ki = 0.14 nM) and human 5-hydroxytryptamine 2A receptor (Ki = 0.81 nM). It also demonstrates bioactivity as an inhibitor of entry for various viruses, including Lassa Virus, Marburg Virus, and Ebola Virus, with potency ranging from 12589.3 nM to 1.413 µM. In the context of SARS-CoV-2, Blonanserin shows minimal antiviral activity in certain assays, with low to moderate inhibition rates observed in different cell lines (e.g., 3.22% inhibition in Caco-2 cells at 10 µM after 48 hours, 28.63% and 5.707% inhibition of 3CL-Pro protease at 20 µM, and approximately 0.11% inhibition in VERO-6 cells at 10 µM). Additionally, it exhibits some inhibition of human HDAC6 activity (17.51% with a commercial peptide substrate), though this activity is inconsistent across different substrates. These findings suggest that while Blonanserin has potent receptor binding and some antiviral properties, its efficacy can vary depending on the specific viral target and experimental conditions..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Blonanserin (AD-5423) is an atypical antipsychotic approved in Japan in January, 2008. Relative to many other antipsychotics, blonanserin has an improved tolerability profile, lacking side effects such as extrapyramidal symptoms, excessive sedation, or hypotension.
Targets&IC50	5-HT2C receptor:26.4 nM (Ki), 5-HT2A receptor:0.812 nM (Ki), 5-HT2:3.98 nM(Ki), D3 receptor:0.494 nM (Ki), α1-adrenoceptor:26.7 nM (Ki, rat), D1 receptor:1070 nM (Ki), D2 receptor:14.8 nM(Ki), 5-HT6 receptor:11.7 nM (Ki), D4 Receptor:150 nM (Ki), α2-adrenoceptor:530 nM (Ki, rat)
In vitro	In tests of atypical antipsychotics (risperidone, olanzapine, and aripiprazole), Blonanserin showed the most potent binding affinity for human D3 receptors.Blonanserin transiently increased neuronal firing in the nucleus of the pallidum and ventral tegmental area, but not in the nucleus medius dorsalis or the medial dorsal nucleus of the thalamus, whereas risperidone increased firing in the nucleus ventral tegmental area and in the nucleus medius dorsalis but not in the nucleus dorsalis. in the medial dorsal nucleus of the rat thalamus. Blonanserin consistently increased additional extracellular levels of norepinephrine and dopamine but not serotonin, GABA, or glutamate, whereas risperidone consistently increased levels of norepinephrine, dopamine, and serotonin but not GABA or glutamate.Blonanserin increased the efflux of cortical DA and its metabolites, homovanillic acid and 3,4-dihydroxy Phenylacetic acid.
In vivo	In tests of atypical antipsychotics (risperidone, olanzapine, and aripiprazole), Blonanserin showed the most potent binding affinity for human D3 receptors.Blonanserin transiently increased neuronal firing in the nucleus of the pallidum and ventral tegmental area, but not in the nucleus medius dorsalis or the medial dorsal nucleus of the thalamus, whereas risperidone increased firing in the nucleus ventral tegmental area and in the nucleus medius dorsalis but not in the nucleus dorsalis. in the medial dorsal nucleus of the rat thalamus. Blonanserin consistently increased additional extracellular levels of norepinephrine and dopamine but not serotonin, GABA, or glutamate, whereas risperidone consistently increased levels of norepinephrine, dopamine, and serotonin but not GABA or glutamate.Blonanserin increased the efflux of cortical DA and its metabolites, homovanillic acid and 3,4-dihydroxy Phenylacetic acid.
Synonyms	AD-5423

Chemical Properties

Molecular Weight	367.50
Formula	C₂₃H₃₀FN₃
Cas No.	132810-10-7
Smiles	FC1=CC=C(C2=C3C(=NC(=C2)N4CCN(CC)CC4)CCCCCC3)C=C1
Relative Density.	1.095 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 14.29 mg/mL (38.88 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1.00 mg/mL (2.72 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.7211 mL	13.6054 mL	27.2109 mL	136.0544 mL
5 mM	0.5442 mL	2.7211 mL	5.4422 mL	27.2109 mL
10 mM	0.2721 mL	1.3605 mL	2.7211 mL	13.6054 mL
20 mM	0.1361 mL	0.6803 mL	1.3605 mL	6.8027 mL

Note : The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc